# Bevacizumab-Induced Cutaneous Lupus Erythematosus in a Patient With Metastatic Colon Carcinoma: A Case Report

## TL;DR

A patient with colon cancer developed cutaneous lupus after bevacizumab treatment, which improved after stopping chemotherapy.

## Contribution

Reports a rare case of bevacizumab-induced cutaneous lupus and highlights the importance of timely intervention.

## Key findings

- Bevacizumab can cause cutaneous lupus as a rare side effect.
- Discontinuation of chemotherapy led to improvement in the patient's condition.
- Early recognition and intervention are crucial for managing this adverse reaction.

## Abstract

Bevacizumab, an anti-vascular epidermal growth factor inhibitor, is approved for the treatment of various cancers. Hypertension, gastrointestinal perforation, bleeding manifestations, impaired wound healing, and cerebrovascular accidents are common side effects associated with the monoclonal antibody. Uncommon cutaneous reactions like exfoliative dermatitis associated with bevacizumab have been documented in the medical literature. We present an unusual case of bevacizumab-induced cutaneous lupus in a patient with metastatic colon cancer that started resolving after discontinuing chemotherapy. Timely intervention was key in preventing the progression of this chemotherapy-induced cutaneous lupus.